Aimovig

Chemical Nameerenumab-aooe
Dosage FormInjectable (subcutaneous; 70 mg/mL, 140 mg/mL)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyAmgen Inc.
Approval Year2018

Indication

  • Aimovig is indicated for the preventive treatment of migraine in adults.
Last updated on 2/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Aimovig (erenumab-aooe) Prescribing Information2019Amgen